These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 11508274

  • 1. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
    Nagisa Y, Shintani A, Nakagawa S.
    Diabetologia; 2001 Jul; 44(7):883-8. PubMed ID: 11508274
    [Abstract] [Full Text] [Related]

  • 2. [Ameliorative effects on retinal disorder in diabetic SHRSP (stroke-prone spontaneously hypertensive rat)].
    Nagisa Y, Shintani A, Nakagawa S.
    Nihon Rinsho; 2002 Oct; 60(10):1975-80. PubMed ID: 12397694
    [Abstract] [Full Text] [Related]

  • 3. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, Yamamoto K, Kato T, Hayakawa N, Oda N, Goto Y, Goto Y, Nagasaka A, Senda T, Itoh M.
    Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats.
    Kagoshima T, Masuda J, Sutani T, Sakaguchi Y, Tsuchihashi M, Tsuruta S, Iwano M, Dohi K, Nakamura Y, Konishi N.
    Blood Press Suppl; 1994 Jul; 5():89-93. PubMed ID: 7889210
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats.
    Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F.
    Blood Press Suppl; 1994 Jul; 5():54-6. PubMed ID: 7889201
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.
    Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H.
    J Pharmacol Exp Ther; 1995 Apr; 273(1):509-15. PubMed ID: 7714806
    [Abstract] [Full Text] [Related]

  • 8. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
    Kanagawa R, Wada T, Sanada T, Ojima M, Inada Y.
    Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
    Pollock DM, Morsing P.
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S116-9. PubMed ID: 9892151
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
    Nishikawa K, Inada Y, Shibouta Y, Wada T, Ojima M, Kubo K, Naka T.
    Blood Press Suppl; 1994 Jan; 5():7-14. PubMed ID: 7889205
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
    Noda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, Nishikawa K, Shibouta Y.
    Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442
    [Abstract] [Full Text] [Related]

  • 18. Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.
    Andersen NH, Knudsen ST, Poulsen PL, Poulsen SH, Helleberg K, Eiskjaer H, Hansen KW, Bek T, Mogensen CE.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):96-9. PubMed ID: 12806591
    [Abstract] [Full Text] [Related]

  • 19. Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats.
    Bennai F, Morsing P, Paliege A, Ketteler M, Mayer B, Tapp R, Bachmann S.
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S104-15. PubMed ID: 9892150
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000 Jan; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.